Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
– Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models HOUSTON May 15, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company), a clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the commencement of an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06) in cooperation with the Company. The study is being conducted under Northwestern University's Investigative New Drug application (IND) which cross references the Company's own IND, which received clearance from the U.S. Food and Drug Administration (FDA) in April 2022 . This trial is funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to bringing awareness to brain cancer.
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaPR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin Participates in Virtual Investor "What this Means" SegmentPR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
MBRX
Sec Filings
- 9/23/24 - Form 8-K
- 9/16/24 - Form 8-K
- 9/16/24 - Form 8-K
- MBRX's page on the SEC website